# FGA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *FGA* gene encodes the alpha chain of fibrinogen, a critical hexameric glycoprotein synthesized primarily in hepatocytes. Its structure comprises an N-terminal E domain, a coiled-coil region, and a C-terminal αC-domain, which contains an RGD motif for platelet integrin αIIbβ3 binding and Factor XIIIa crosslinking sites.
- Pathogenic variants in *FGA* lead to congenital fibrinogen disorders, including afibrinogenemia (autosomal recessive, null variants), hypofibrinogenemia (autosomal dominant, reduced levels), and dysfibrinogenemia (autosomal dominant, qualitative defects). Specific mutations in the fibrinopeptide A region (e.g., p.Arg16His) or αC-domain (e.g., p.Arg573His) are associated with severe bleeding or paradoxical thrombosis.
- Beyond hemostasis, fibrinogen alpha chain participates in innate immune modulation and angiogenesis. It binds to leukocyte integrin Mac-1 and its αC-domain can release cryptic anti-angiogenic motifs, influencing inflammatory cell recruitment and vascular development.
- Fibrinogen is a positive acute-phase reactant, with its transcription upregulated by IL-6 via STAT3 signaling, contributing to the prothrombotic state observed in inflammation and infection. Bacterial pathogens like *Staphylococcus aureus* and *Streptococcus pyogenes* exploit the αC-domain for adherence and immune evasion.
- Therapeutic strategies for *FGA*-related disorders include fibrinogen concentrate replacement for afibrinogenemia and cryoprecipitate for acute bleeding. Investigational approaches include gene therapy using AAV vectors to restore hepatic fibrinogen production and small-molecule inhibitors targeting fibrinogen receptor interactions or thrombin.

---

## Executive Summary & Key Metadata

The **FGA** gene encodes the alpha chain of fibrinogen, a hexameric glycoprotein central to hemostasis, wound healing, and inflammatory responses. Fibrinogen is converted to fibrin by thrombin, forming the structural scaffold of blood clots. Beyond its canonical role in coagulation, the fibrinogen alpha chain (Aα) participates in platelet aggregation, angiogenesis, and innate immune modulation. Pathogenic variants in *FGA* cause congenital fibrinogen disorders, including afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia, with phenotypes ranging from severe bleeding to thrombosis. This reference manual provides a comprehensive analysis of the *FGA* gene, from genomic architecture to clinical translation.

| **Attribute** | **Detail** |
|---------------|------------|
| HGNC Symbol | FGA |
| UniProt Accession | P02671 |
| Representative PDB ID | 3GHG (fibrinogen fragment D) |
| Chromosomal Locus | 4q31.3 |
| Gene Size | ~7.5 kb (11 exons) |
| Primary Molecular Function | Coagulation factor; fibrin clot formation; platelet aggregation ligand |
| Disease Associations | Congenital afibrinogenemia (AR), hypofibrinogenemia (AD), dysfibrinogenemia (AD), renal amyloidosis (AD) |
| Expression Pattern | Hepatocyte-specific (liver); minor extrahepatic expression |
| Post-Translational Modifications | N-linked glycosylation (Asn-78), phosphorylation, sulfation, crosslinking (FXIIIa) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *FGA* gene is located on the long arm of chromosome 4 at cytogenetic band **4q31.3**, spanning approximately 7.5 kilobases of genomic DNA. The gene is oriented on the minus strand (reverse orientation) relative to the chromosome. The precise genomic coordinates (GRCh38/hg38) are chr4:154,583,126–154,590,742. *FGA* resides within a tightly clustered fibrinogen gene family locus, flanked by *FGB* (fibrinogen beta chain) and *FGG* (fibrinogen gamma chain) in a head-to-head-to-tail arrangement: 5′–*FGG*–*FGB*–*FGA*–3′. This ~50 kb locus on 4q31.3 is evolutionarily conserved, reflecting the shared ancestry of the three fibrinogen chains.

The *FGA* gene comprises **11 exons** and **10 introns**, with a canonical transcript (NM_000508.5) of 2,555 base pairs. The coding sequence (CDS) spans 1,932 nucleotides, encoding a 644-amino-acid pre-proprotein. The mature Aα chain, after cleavage of the 19-residue signal peptide and 16-residue N-terminal propeptide, is 609 amino acids in length. Exon sizes range from 54 bp (exon 3) to 246 bp (exon 5), with introns varying from 200 bp to 1.2 kb. The promoter region lacks a canonical TATA box but contains a CCAAT box and multiple GC-rich elements, characteristic of constitutively expressed hepatic genes.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *FGA* promoter spans approximately 500 bp upstream of the transcription start site (TSS). Functional characterization has identified several critical cis-regulatory elements:

- **HNF-1 (Hepatic Nuclear Factor-1) binding site** at −82 to −70 bp: This element is indispensable for basal hepatic transcription. HNF-1α and HNF-1β heterodimers bind this site, recruiting coactivators such as CBP/p300.
- **CCAAT/enhancer-binding protein (C/EBP) motifs** at −110 to −90 bp and −220 to −200 bp: C/EBPα and C/EBPβ synergize with HNF-1 to drive high-level expression in hepatocytes.
- **Interleukin-6 (IL-6) response elements (IL-6RE)** at −290 to −270 bp: These elements bind STAT3, mediating the acute-phase response. During inflammation, IL-6 signaling upregulates *FGA* transcription, increasing fibrinogen production.
- **Glucocorticoid response elements (GREs)**: Dexamethasone and other glucocorticoids enhance *FGA* transcription via direct receptor binding, explaining the elevation of fibrinogen in stress states.

Enhancer elements have been mapped to intron 1 and intron 3, which contain binding sites for hepatocyte-enriched transcription factors (HNF-3/forkhead, HNF-4). Chromatin immunoprecipitation (ChIP) studies confirm that these intronic enhancers loop to the promoter in hepatocytes, maintaining an active chromatin state marked by H3K4me3 and H3K27ac.

### 1.3 Alternative Splicing and Isoforms

The *FGA* gene undergoes alternative splicing, generating multiple transcript variants:

- **Transcript variant 1 (NM_000508.5)**: Encodes the full-length Aα chain (644 aa). This is the predominant isoform in plasma.
- **Transcript variant 2 (NM_021871.4)**: Uses an alternative splice donor site in exon 5, leading to a frameshift and premature termination. This produces a truncated Aα-E isoform (236 aa) that is secreted and incorporated into fibrinogen molecules at low levels.
- **Transcript variant 3 (NM_001363758.2)**: Retains intron 5, introducing a premature stop codon. This isoform is subject to nonsense-mediated decay (NMD) and is likely a regulatory transcript.

The Aα-E isoform, also known as fibrinogen alpha-E, is a naturally occurring extended variant that includes an additional C-terminal globular domain. It constitutes <1% of circulating fibrinogen but has altered biophysical properties, including increased resistance to plasmin degradation.

### 1.4 Epigenetic Regulation

DNA methylation analysis of the *FGA* promoter in hepatocytes reveals hypomethylation at CpG islands, correlating with active transcription. In non-hepatic tissues, hypermethylation silences the gene. Histone modifications at the *FGA* locus are dynamically regulated during the acute-phase response: IL-6 stimulation induces H3K9 acetylation and H3K4me1 at enhancer regions within 30 minutes of cytokine exposure.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The fibrinogen Aα chain (UniProt P02671) is a 644-amino-acid polypeptide with a modular architecture. The mature protein (after signal and propeptide cleavage) is organized into distinct structural and functional domains:

| **Domain** | **Residues (mature)** | **Function** |
|------------|----------------------|--------------|
| N-terminal central E domain | 1–35 | Disulfide-linked assembly with Bβ and γ chains; thrombin cleavage site (Arg-16–Gly-17) |
| Coiled-coil region | 36–197 | α-helical coiled-coil; connects central E to peripheral D domains; flexible hinge |
| Plasmin-sensitive region | 198–391 | Unstructured; contains plasmin cleavage sites; highly glycosylated |
| C-terminal globular domain | 392–609 | αC-domain; binds platelets (αIIbβ3), endothelial cells, and fibroblasts; calcium-binding site |

The N-terminal region (residues 1–35) contains the fibrinopeptide A (FpA) sequence, which is cleaved by thrombin at the Arg-16–Gly-17 bond. This cleavage exposes polymerization knobs (Gly-Pro-Arg motifs) that interact with complementary holes in the γ chains of adjacent fibrin molecules, driving fibrin polymerization.

### 2.2 Secondary and Tertiary Structure

The coiled-coil region (residues 36–197) forms a parallel three-stranded α-helical bundle with the Bβ and γ chains. This region is stabilized by interchain disulfide bonds at Cys-45, Cys-72, and Cys-197, which covalently link the three chains. The coiled-coil is interrupted by two short non-helical segments that confer flexibility, allowing the molecule to bend during clot formation.

The C-terminal αC-domain (residues 392–609) is intrinsically disordered in solution but folds into a globular structure upon calcium binding or interaction with integrins. This domain contains:

- **Calcium-binding site**: Coordinates a single Ca²⁺ ion via Asp-476, Asp-478, and Glu-480, stabilizing the folded conformation.
- **Integrin-binding motif**: The sequence Arg-Gly-Asp (RGD) at positions 572–574 mediates binding to platelet integrin αIIbβ3 (GPIIb/IIIa).
- **Factor XIIIa crosslinking sites**: Lys-508 and Gln-562 participate in isopeptide bond formation, stabilizing the fibrin clot.

### 2.3 Quaternary Structure: The Fibrinogen Hexamer

Fibrinogen is a 340 kDa hexamer composed of two copies of each chain (Aα, Bβ, γ), arranged symmetrically as (AαBβγ)₂. The six chains are linked by 29 disulfide bonds, forming a trinodular structure: a central E domain connected by two coiled-coil rods to peripheral D domains. The αC-domains extend from the D regions and interact with the central E domain in the native molecule.

The crystal structure of fibrinogen fragment D (PDB: 3GHG) reveals the detailed architecture of the C-terminal regions of all three chains. The αC-domain is visible in the crystal as a globular fold with a central β-sheet flanked by α-helices.

### 2.4 Interactive 3D Visualization

For interactive exploration of the FGA protein structure, including domain boundaries, post-translational modifications, and pathogenic variant locations, use the dedicated visualizer:

[Interactive 3D Protein Visualizer: Load FGA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P02671)

This tool allows rotation, zoom, and residue-level annotation of the fibrinogen alpha chain within the context of the hexameric complex.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Coagulation Cascade and Fibrin Formation

FGA is a terminal substrate of the coagulation cascade. The extrinsic and intrinsic pathways converge on the activation of thrombin (factor IIa), which cleaves fibrinopeptides A and B from the Aα and Bβ chains, respectively. Fibrinopeptide A cleavage (Arg-16–Gly-17) is the rate-limiting step, exposing the Gly-Pro-Arg polymerization knob. This knob binds to the "a" hole in the γ-chain of another fibrin molecule, initiating longitudinal and lateral polymerization.

The resulting fibrin polymer is a branched network that provides the structural scaffold for the clot. Factor XIIIa (activated transglutaminase) crosslinks adjacent fibrin molecules via ε-(γ-glutamyl)lysine isopeptide bonds between Gln-398 and Lys-406 of the αC-domains, increasing clot stiffness and resistance to fibrinolysis.

### 3.2 Platelet Aggregation and Integrin Signaling

The αC-domain of FGA contains an RGD motif (Arg-572–Gly-573–Asp-574) that binds to the activated platelet integrin αIIbβ3. This interaction is essential for platelet aggregation: fibrinogen bridges adjacent activated platelets, crosslinking them via αIIbβ3. The binding triggers outside-in signaling through the integrin, activating Src family kinases, focal adhesion kinase (FAK), and downstream PI3K/Akt pathways, leading to platelet spreading and granule secretion.

### 3.3 Fibrinolysis and Plasminogen Activation

Fibrin serves as a cofactor for plasminogen activation by tissue plasminogen activator (tPA). The αC-domain contains lysine residues that bind plasminogen and tPA, bringing them into proximity and accelerating plasmin generation. Plasmin cleaves fibrin at specific sites within the coiled-coil and αC regions, generating fibrin degradation products (D-dimers, E fragments). The unstructured plasmin-sensitive region (residues 198–391) is the primary target, with cleavage sites at Lys-206, Lys-219, and Arg-239.

### 3.4 Inflammatory and Angiogenic Signaling

Beyond hemostasis, FGA and its cleavage products modulate inflammation and angiogenesis:

- **Fibrinogen binding to leukocyte integrin Mac-1 (αMβ2)**: The γ-chain (not α) mediates this interaction, but the αC-domain contributes to leukocyte adhesion and transmigration.
- **Angiogenic regulation**: The αC-domain contains a cryptic anti-angiogenic motif (residues 392–610) that is exposed upon proteolysis. This fragment inhibits endothelial cell proliferation and migration by blocking VEGF signaling.
- **Acute-phase response**: Fibrinogen is a positive acute-phase protein, with plasma levels rising 2–10 fold during inflammation. IL-6 and IL-1β synergistically upregulate *FGA* transcription via STAT3 and NF-κB pathways.

### 3.5 Protein-Protein Interaction Network

The FGA protein interacts with numerous partners, as catalogued in BioGRID and STRING databases:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|----------------|---------------------|----------------------------|
| FGB (fibrinogen beta) | Covalent (disulfide) | Hexamer assembly |
| FGG (fibrinogen gamma) | Covalent (disulfide) | Hexamer assembly |
| Thrombin (F2) | Enzymatic cleavage | Fibrinopeptide release |
| Factor XIIIa | Transglutamination | Clot crosslinking |
| Integrin αIIbβ3 (ITGA2B/ITGB3) | Receptor-ligand | Platelet aggregation |
| Plasminogen (PLG) | Cofactor binding | Fibrinolysis |
| Tissue plasminogen activator (PLAT) | Cofactor binding | Plasmin generation |
| Fibroblast growth factor-2 (FGF2) | Non-covalent | Angiogenesis modulation |
| Vascular endothelial growth factor (VEGF) | Non-covalent | Angiogenesis inhibition |

### 3.6 Regulatory Feedback Loops

Fibrinogen expression is regulated by a negative feedback loop involving thrombin. Thrombin activates protease-activated receptors (PARs) on hepatocytes, which downregulate *FGA* transcription via protein kinase C (PKC) and MAPK pathways. This ensures that fibrinogen production is titrated to coagulation demand. Additionally, fibrin degradation products (D-dimers) inhibit *FGA* transcription by binding to the promoter region via a nuclear receptor complex, providing a second feedback mechanism.

```mermaid
sequenceDiagram
    participant IL6 as "IL-6"
    participant GP as "gp130/JAK"
    participant STAT as "STAT3"
    participant NUC as "Nucleus"
    participant FGA as "FGA Gene"
    participant MRNA as "FGA mRNA"
    participant PROT as "Fibrinogen Aα"
    participant THR as "Thrombin"
    participant FIB as "Fibrin Clot"
    participant PLAS as "Plasmin"
    participant DIM as "D-dimers"
    IL6->>GP: Cytokine binding
    GP->>STAT: Phosphorylation (Y705)
    STAT->>NUC: Dimerization & translocation
    NUC->>FGA: Binds IL-6RE in promoter
    FGA->>MRNA: Transcription
    MRNA->>PROT: Translation in hepatocytes
    PROT->>THR: Secreted to plasma
    THR->>FIB: Cleaves FpA/FpB → fibrin
    FIB->>PLAS: Cofactor for tPA
    PLAS->>DIM: Degrades fibrin
    DIM->>NUC: Inhibits FGA transcription (feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Classification of Fibrinogen Disorders

Pathogenic variants in *FGA* cause a spectrum of congenital fibrinogen disorders, classified by quantitative and qualitative defects:

| **Disorder** | **Inheritance** | **Fibrinogen Level** | **Molecular Defect** |
|--------------|----------------|---------------------|---------------------|
| Afibrinogenemia | Autosomal recessive | Undetectable | Homozygous/compound heterozygous null variants |
| Hypofibrinogenemia | Autosomal dominant | 50–100 mg/dL (low) | Heterozygous null variants |
| Dysfibrinogenemia | Autosomal dominant | Normal or low | Missense variants affecting function |
| Hypodysfibrinogenemia | Autosomal dominant | Low + dysfunctional | Compound variants |

### 4.2 Afibrinogenemia-Causing Mutations

Afibrinogenemia (OMIM #202400) is the most severe phenotype, presenting with umbilical cord bleeding at birth, intracranial hemorrhage, and spontaneous splenic rupture. More than 100 pathogenic variants have been reported in *FGA*:

- **Nonsense mutations**: c.501C>T (p.Arg167Ter) is the most common null allele in Caucasian populations, introducing a premature stop codon in the coiled-coil region. The truncated protein is not secreted, and the mRNA is degraded by NMD.
- **Frameshift mutations**: c.1129delG (p.Glu377LysfsTer23) in exon 5 causes a frameshift and premature termination. This variant is prevalent in non-Caucasian populations.
- **Splice-site mutations**: c.510+1G>T disrupts the donor splice site of intron 4, leading to exon skipping and a frameshift.
- **Large deletions**: Whole-exon deletions (e.g., exons 2–5) have been reported, resulting in complete absence of the Aα chain.

### 4.3 Dysfibrinogenemia Hotspots

Dysfibrinogenemia (OMIM #616004) results from missense mutations that impair fibrinopeptide release, polymerization, or crosslinking. Key hotspots include:

- **Fibrinopeptide A region (residues 1–16)**:
  - **p.Arg16His (Fibrinogen Naples)**: This mutation abolishes thrombin cleavage at Arg-16, preventing fibrinopeptide A release. Patients exhibit severe bleeding and defective clot formation. The variant is located in the thrombin-binding pocket, disrupting the P1 arginine.
  - **p.Arg16Cys (Fibrinogen Metz)**: Similar to Arg16His, this variant prevents thrombin cleavage but also introduces a free cysteine that forms aberrant disulfide bonds, leading to intracellular retention.

- **Polymerization knob region (residues 17–20)**:
  - **p.Gly17Val (Fibrinogen Pontoise)**: Substitution of glycine with valine in the Gly-Pro-Arg knob disrupts knob-hole interactions, impairing lateral aggregation. Patients have a bleeding diathesis.
  - **p.Pro18Leu (Fibrinogen Chapel Hill III)**: This variant alters the conformation of the polymerization knob, reducing binding affinity for the γ-chain hole.

- **αC-domain (residues 392–609)**:
  - **p.Arg573His (Fibrinogen Dusart)**: Located within the RGD integrin-binding motif, this mutation abolishes platelet aggregation. Patients present with mild bleeding and impaired wound healing.
  - **p.Gln562Pro (Fibrinogen Caracas II)**: Disrupts Factor XIIIa crosslinking, resulting in a mechanically weak clot that is susceptible to premature fibrinolysis.

### 4.4 Thrombotic Phenotypes

Paradoxically, some *FGA* mutations cause thrombosis rather than bleeding:

- **p.Arg554Lys (Fibrinogen New York I)**: This variant enhances thrombin binding to fibrin, increasing clot resistance to plasmin degradation. Patients have recurrent venous thromboembolism.
- **p.Asp318Tyr (Fibrinogen Paris V)**: Alters calcium binding in the αC-domain, leading to abnormal fibrin polymerization with increased clot stiffness and resistance to fibrinolysis.

### 4.5 Renal Amyloidosis

A distinct phenotype, hereditary renal amyloidosis (OMIM #105200), is caused by specific *FGA* mutations that produce amyloidogenic fragments:

- **p.Glu526Val (Fibrinogen Aα-chain Val526)**: The most common amyloidogenic variant. The mutant αC-domain is proteolytically cleaved, generating a 49-residue fragment (residues 500–548) that misfolds into β-sheet-rich amyloid fibrils. These fibrils deposit in the renal glomeruli, causing progressive proteinuria and renal failure.
- **p.Arg554Leu (Fibrinogen Aα-chain Leu554)**: Another amyloidogenic variant, producing a fragment that forms fibrils with a distinct morphology.

### 4.6 ClinVar Classification Summary

As of the latest ClinVar release, *FGA* contains:

- **Pathogenic/Likely pathogenic**: 187 variants
- **Benign/Likely benign**: 45 variants
- **Variants of uncertain significance (VUS)**: 212 variants

The majority of pathogenic variants are concentrated in exons 2 (FpA region), 4 (coiled-coil), and 5 (plasmin-sensitive region).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Interactions with Fibrinogen

Fibrinogen serves as a critical host factor for multiple bacterial pathogens, which have evolved surface proteins that bind FGA to evade immune clearance:

- **Staphylococcus aureus**: Expresses clumping factor A (ClfA) and fibronectin-binding proteins (FnBPs) that bind the αC-domain of FGA. This interaction promotes bacterial aggregation and shields the pathogen from phagocytosis. The S. aureus protein Efb (extracellular fibrinogen-binding protein) binds the αC-domain, inhibiting complement-mediated opsonization.
- **Streptococcus pyogenes**: The M protein binds fibrinogen via the αC-domain, facilitating adherence to host cells and resistance to antimicrobial peptides. The streptococcal inhibitor of complement (SIC) also interacts with FGA to block complement activation.
- **Yersinia pestis**: The plasminogen activator (Pla) protease cleaves FGA, degrading fibrin clots and promoting bacterial dissemination. This activity is essential for the fulminant septicemia characteristic of plague.

### 5.2 Viral Interactions

Several viruses exploit fibrinogen for entry or immune evasion:

- **Hepatitis C virus (HCV)**: HCV core protein binds fibrinogen, leading to its accumulation in hepatocytes and contributing to the coagulopathy observed in chronic infection.
- **Dengue virus**: The NS1 protein interacts with fibrinogen, reducing its availability and contributing to the hemorrhagic manifestations of severe dengue.
- **SARS-CoV-2**: COVID-19 is associated with hyperfibrinogenemia and microthrombi. The viral spike protein has been shown to bind fibrinogen, potentially enhancing clot formation and contributing to the prothrombotic state.

### 5.3 Parasitic Interactions

- **Plasmodium falciparum**: The parasite's erythrocyte membrane protein 1 (PfEMP1) binds fibrinogen, facilitating cytoadherence of infected erythrocytes to vascular endothelium and contributing to cerebral malaria pathogenesis.

### 5.4 Immune Evasion Mechanisms

Fibrinogen degradation products (FDPs) generated by bacterial proteases have immunosuppressive effects. FDPs inhibit T-cell proliferation, suppress natural killer (NK) cell cytotoxicity, and impair macrophage phagocytosis. This creates a local immunosuppressive niche that favors pathogen survival.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Fibrinogen as a Therapeutic Target

Given its central role in thrombosis and inflammation, FGA is a target for multiple therapeutic strategies:

| **Drug/Agent** | **Class** | **Mechanism** | **Clinical Use** |
|----------------|-----------|---------------|------------------|
| Fibrinogen concentrate (RiaSTAP) | Plasma-derived concentrate | Replaces deficient FGA | Congenital afibrinogenemia; acquired hypofibrinogenemia |
| Cryoprecipitate | Blood product | Contains fibrinogen, FVIII, vWF | Acute bleeding with low fibrinogen |
| Defibrotide | Polydeoxyribonucleotide | Modulates fibrinogen binding to endothelium | Hepatic veno-occlusive disease |
| Batroxobin (Reptilase) | Snake venom enzyme | Cleaves FpA only (not FpB) | Diagnostic reagent; investigational hemostatic |
| Ancrod | Snake venom enzyme | Cleaves FpA, depletes fibrinogen | Investigational anticoagulant (withdrawn) |

### 6.2 Investigational Small Molecules

- **Fibrinogen receptor antagonists**: Small molecules targeting the αIIbβ3-binding RGD motif in the αC-domain. While peptide mimetics (e.g., eptifibatide, tirofiban) target the integrin rather than FGA, they block the FGA-αIIbβ3 interaction and are FDA-approved for acute coronary syndromes.
- **Thrombin inhibitors**: Direct thrombin inhibitors (dabigatran, argatroban) prevent FpA cleavage, indirectly inhibiting FGA function. These are widely used anticoagulants.
- **FXIIIa inhibitors**: Investigational agents (e.g., ZED-1227) that block fibrin crosslinking, potentially useful as profibrinolytic agents.

### 6.3 Gene Therapy Approaches

Preclinical studies have explored adeno-associated virus (AAV) vectors delivering the *FGA* cDNA to hepatocytes for the treatment of afibrinogenemia. AAV8-FGA vectors have shown sustained expression of functional fibrinogen in murine models, with correction of bleeding phenotype for up to 6 months. Clinical trials are in early phases.

### 6.4 Pharmacogenomic Considerations

- **FGA polymorphisms and drug response**: The common *FGA* polymorphism c.1038A>G (p.Thr346Ala) has been associated with variable response to fibrinogen concentrate therapy, though the clinical significance remains unclear.
- **Anticoagulant monitoring**: Patients with dysfibrinogenemia may have falsely elevated or decreased clotting times (PT, aPTT) depending on the mutation, complicating anticoagulant management. Clauss fibrinogen assays are preferred for monitoring.

### 6.5 Anti-fibrinogen Monoclonal Antibodies

- **T2G1**: A monoclonal antibody specific for fibrinogen containing the FpA cleavage site. Used in research to detect fibrin formation in vivo.
- **59D8**: Targets the N-terminus of the β-chain, used in experimental thrombosis imaging.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|--------------|------------------|---------|
| NCBI Gene | 2243 | https://www.ncbi.nlm.nih.gov/gene/2243 |
| Ensembl | ENSG00000171560 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171560 |
| UniProt | P02671 | https://www.uniprot.org/uniprotkb/P02671 |
| RCSB PDB | 3GHG (fragment D) | https://www.rcsb.org/structure/3GHG |
| OMIM | 134820 (FGA) | https://www.omim.org/entry/134820 |
| ClinVar | Gene: FGA | https://www.ncbi.nlm.nih.gov/clinvar/?term=FGA |
| HGMD | FGA | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FGA |
| STRING | P02671 | https://string-db.org/network/P02671 |
| BioGRID | 108606 | https://thebiogrid.org/108606 |
| Gene Ontology (GO) | GO:0007596 (blood coagulation), GO:0005201 (extracellular matrix structural constituent) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-140877 (Formation of Fibrin Clot) | https://reactome.org/content/detail/R-HSA-140877 |
| KEGG | hsa:2243 | https://www.genome.jp/dbget-bin/www_bget?hsa:2243 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem. 2017;82:405-456. doi:10.1007/978-3-319-49674-0_13. https://link.springer.com/chapter/10.1007/978-3-319-49674-0_13

2. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894-1904. doi:10.1111/j.1538-7836.2005.01365.x. https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2005.01365.x

3. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595. doi:10.1055/s-0033-1349222. https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0033-1349222

4. Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42(4):366-374. doi:10.1055/s-0036-1571339. https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0036-1571339

5. Neerman-Arbez M, de Moerloose P, Bridel C, et al. Mutations in the fibrinogen alpha gene account for the majority of cases of congenital afibrinogenemia. Blood. 2000;96(1):149-152. doi:10.1182/blood.V96.1.149. https://ashpublications.org/blood/article/96/1/149/166497

6. Benson MD, Liepnieks JJ, Uemichi T, et al. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet. 1993;3(3):252-255. doi:10.1038/ng0393-252. https://www.nature.com/articles/ng0393-252

7. Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest. 1994;93(2):731-736. doi:10.1172/JCI117027. https://www.jci.org/articles/view/117027

8. Lounes KC, Lefebvre P, Delsaut C, et al. A novel variant fibrinogen (Fibrinogen Caracas II) with impaired polymerization and cross-linking. Blood Coagul Fibrinolysis. 2000;11(4):367-374. doi:10.1097/00001721-200006000-00008. https://journals.lww.com/bloodcoagulation/abstract/2000/06000/a_novel_variant_fibrinogen__fibrinogen_caracas_ii_.8.aspx

9. Koopman J, Haverkate F, Grimbergen J, et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest. 1993;91(4):1637-1643. doi:10.1172/JCI116371. https://www.jci.org/articles/view/116371

10. Ridgway HJ, Brennan SO, Loreth RM, et al. Fibrinogen New York I: a novel A alpha-chain mutation (Arg554Lys) causing impaired fibrin polymerization and thromboembolic disease. Thromb Haemost. 1997;78(4):1168-1173. https://pubmed.ncbi.nlm.nih.gov/9365000/

11. Fuss C, Palmaz JC, Sprague EA. Fibrinogen: structure, function, and surface interactions. J Vasc Interv Radiol. 2001;12(6):677-682. doi:10.1016/s1051-0443(07)61437-7. https://www.sciencedirect.com/science/article/pii/S1051044307614377

12. Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2017;37(3):e13-e21. doi:10.1161/ATVBAHA.117.308564. https://www.ahajournals.org/doi/10.1161/ATVBAHA.117.308564

13. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost. 2006;4(5):932-939. doi:10.1111/j.1538-7836.2006.01861.x. https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2006.01861.x

14. Adams RA, Schachtrup C, Davalos D, et al. Fibrinogen signal transduction as a mediator of inflammatory responses. Sci Signal. 2007;2007(406):pe55. doi:10.1126/stke.4062007pe55. https://www.science.org/doi/10.1126/stke.4062007pe55

15. Ryu JK, Davalos D, Akassoglou K. Fibrinogen signal transduction in the nervous system. J Thromb Haemost. 2009;7(Suppl 1):151-154. doi:10.1111/j.1538-7836.2009.03438.x. https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03438.x

16. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511-520. doi:10.1182/blood-2018-07-818211. https://ashpublications.org/blood/article/133/6/511/260870

17. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood). 2004;229(11):1105-1110. doi:10.1177/153537020422901106. https://journals.sagepub.com/doi/10.1177/153537020422901106

18. Degen JL, Drew AF, Palumbo JS, et al. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci. 2001;936:276-290. doi:10.1111/j.1749-6632.2001.tb03516.x. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2001.tb03516.x

19. Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol. 2007;14(3):236-241. doi:10.1097/MOH.0b013e3280dce578. https://journals.lww.com/co-hematology/abstract/2007/05000/fibrinogen_and_fibrin__scaffold_proteins_in.8.aspx

20. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997;389(6650):455-462. doi:10.1038/38947. https://www.nature.com/articles/38947